Pharmaceutical

#Biopharma #Pharmaceutical #RedHill Biopharma

Cumberland Pharmaceuticals invests $4 million in Talicia

Specialty pharmaceuticals company Cumberland Pharmaceuticals has invested $4 million in Talicia, the global product developed by biopharmaceutical company RedHill Biopharma.  Talicia is the number one branded US gastroenterologist-prescribed H. pylori therapy, listed as a first-line H. pylori therapy in American College of Gastroenterology Clinical Guidelines. It remains the only FDA-approved all-in-one,… Read More

#Business & Investment #News

#Drug Discovery 2022 #ELRIG #Pharmaceutical

Back to business: ELRIG Drug Discovery 2022

DDW Editor Reece Armstrong looks ahead to ELRIG Drug Discovery 2022 and why he and the team are excited to attend. It’s no secret that over the past couple of years, tradeshows within the life sciences sector, and indeed in general across the globe, have taken a massive hit. The… Read More

#Exclusive Content

AI
#AI #Funding #Pharmaceutical

AI platform for pharma raises €12.1 million  

Technology company PeakData has raised €12.1 million in Series A funding to support its artificial intelligence (AI) platform.  Launched in 2018, PeakData enables pharmaceutical companies to uncover the whole therapeutic area by mapping the healthcare professionals (HCPs) most relevant to their target market. It’s hoped that this… Read More

#News

#Clinical trials #Diversity #Pharmaceutical #Pharmaceutical research #Rare disease

The company bringing patients to clinical trials  

DDW’s Reece Armstrong speaks to Scott Gray, President & CEO of Clincierge about its unique approach to improving the clinical trial experience for patients.   For patients participating in a clinical trial, the experience can be one of considerable hardship, both from a perspective on their health and the impact… Read More

#Exclusive Content #Opinion

Antibodies
#Antibody #Pharmaceutical

Absolute Antibody expands humanised services  

Absolute Antibody has expanded it Prometheus antibody humanisation service to deliver humanised antibodies from a wider range of species than it had previously had.   The company’s Prometheus antibody humanisation service now offers humanisation from -murine origin species, including rabbit antibodies and single-domain camelid nanobodies.  Humanisation… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug discovery #Pharmaceutical #Therapeutics #Women in STEM

International Women’s Day: Female achievement in drug discovery

The theme for International Women’s Day 2022 is ‘Break the Bias’, in which society is encouraged to celebrate women’s achievements, in turn raising awareness against bias and inspiring positive action for equality. Though the initiative is interdisciplinary, the drug discovery, life science and pharmaceutical world boasts many achievements of this… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trending News

#Drug development #Drug discovery #Drug research #Pharmaceutical #Zebrafish

Appointment to help bridge the gap between isolated systems

The MDI Biological Laboratory (MDIBL) has appointed James Strickland as Director of MDI Bioscience, a new initiative focused on using non-mammalian models in early drug discovery and development.   Background  Strickland brings experience in pharmaceutical development to his new position, in which he will leverage… Read More

#News

#Clinical trials #Collaboration #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical #Research

Early trial of first multivariant Covid-19 vaccine booster begins

A Phase I clinical trial of the world’s first multivariant Covid-19 vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester UK and Manchester University NHS Foundation Trust.  Initially involving participants aged 60+, its creators say the drug, GRT-R910, can boost… Read More

#News

#AI / data analytics / healthtech / informatics #Deep learning #Drug discovery #Pharmaceutical

Opportunities and challenges for AI in drug discovery

By Naheed Kurji, Co-founder and Executive of the Alliance for Artificial Intelligence in Healthcare (AAIH), CEO of Cyclica; and Andreas Windemuth, Ph.D, Chief Science Officer of Cyclica Over the past decade, a new industry has arisen that seeks to apply artificial intelligence (AI), or more aptly machine learning (ML) technologies,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#Biotherapeutics #Cell and gene therapy #Pharmaceutical #Therapeutics

Sector trio enters R&D alliance to develop cell therapies for eye diseases

BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics have entered a strategic research joint venture focused on developing cell therapies for patients with ocular diseases. The companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have… Read More

#News

#Biotherapeutics #Cancer research #Drug development #Immuno-oncology #Pharmaceutical

Janssen seeks approval for refractory multiple myeloma drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Read More

#Cancer Research #News

#Immunology / Virology & Vaccines #Life sciences #mRNA #Pharmaceutical

What the UK Budget means for the pharma sector: industry reaction

By Lu Rahman In his 2021 Budget, UK Chancellor of the Exchequer, Rishi Sunak, announced a range of measures designed to benefit UK science, business and technology. These included tax breaks for firms to designed to ‘unlock’ £20bn worth of business investment; incentives for companies to take on apprentices; allowing… Read More

#Editor's Choice #News #Trending News

#Biotechnology #Coronavirus #Covid-19 #Drug development #Drug discovery #Metabolomics #Metabolon #Narrated podcasts #Pharmaceutical

The potential of metabolomics & COVID-19 Vaccine Development

Today’s episode is titled The potential of metabolomics & COVID-19 Vaccine Development, and covers 2 articles taken from the most recent Fall issue of DDW. These articles are titled: Why metabolomics has the potential to transform diagnosis and treatment. & COVID-19 Vaccine Development: dethroning evil King Coronavirus These articles were firstly… Read More

#Podcasts

#Biotechnology #Clinical trials #Drug development #Pharmaceutical

New psychedelic medicine COO looks to boost pharma and biotech collaborations

Beckley Psytech, a company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer. Page brings over 25 years’ experience working within global pharmaceutical and medtech organisations in strategic and operation roles. He started his career at SmithKline Beecham before joining… Read More

#Editor's Choice #News

#Biotechnology #CRISPR #Genomics #Pharmaceutical #Zebrafish

ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement

ERS Genomics and ZeClinics have announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio. ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier. ZeClinics is a contract research organisation using zebrafish to carry out services… Read More

#News